AbCellera Secures Global Settlement and Patent License Deal
I'm PortAI, I can summarize articles.
AbCellera Biologics announced a global settlement and patent license agreement with Bruker Corporation, resolving all patent litigation. Bruker will pay $36 million upfront and ongoing royalties on sales of its Beacon Optofluidic platform products. This deal strengthens AbCellera's cash position and provides a revenue stream. Despite this, analysts rate AbCellera stock as Hold, citing financial challenges and unattractive valuation. AbCellera, a clinical-stage biotech company, focuses on antibody-based medicines in various therapeutic areas.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments